Dr. Esteva is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lenox Hill Hospital
210 East 64th Street
New York, NY 10065Phone+1 212-434-4460
Summary
- Dr. Francisco Esteva, MD, located in New York, NY, specializes in Oncology with a focus on Breast Cancer. His education includes an Oncology Fellowship at Georgetown University Hospital and Internal Medicine Residency at Cooper Medical School of Rowan University. Prior to his current position as Division Chief at Lenox Hill Hospital, Dr. Esteva has held professorship positions at NYU and The University of Texas MD Anderson Cancer Center, as well as serving as VP Clinical Development for Cellectis. In addition to multiple esteemed publications, he has led several clinical trials related to Breast Cancer treatments. Dr. Esteva was elected as a member of The American Society for Clinical Investigation in 2010 and recognized as a Fellow by the American College of Physicians in 2002.
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1994 - 1996
Cooper Medical School of Rowan University/Cooper University HospitalResidency, Internal Medicine, 1991 - 1994
Universidad de Zaragoza Faculty of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 2008 - Present
NY State Medical License 2013 - 2026
TX State Medical License 1998 - 2015
DC State Medical License 1994 - 2003
VA State Medical License 1996 - 2000
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
- Fellow (FACP) American College of Physicians, 2002
Clinical Trials
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer Start of enrollment: 2006 Apr 01
- The Impact of Obesity and Obesity Treatments on Breast Cancer Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsTailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.Francisco J Esteva, Elena Katz
JCO Oncology Practice. 2024-08-01 - 2 citationsLong-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic t...Xuexin He, Jiali Ji, Aiham Qdaisat, Francisco J Esteva, Sai-Ching J Yeung
Lancet Regional Health. Americas. 2024-04-01 - 5 citationsNext-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.Brittney S Zimmerman, Francisco J Esteva
Cancers. 2024-02-16
Journal Articles
- Expression of Human Endogenous Retrovirus-K Is Strongly Associated with the Basal-like Breast Cancer PhenotypeFrancisco J Esteva, Nature
Press Mentions
New Classification of HER2–Ultra-Low Breast Cancer: What Do We Need to Know?December 19th, 2024- 10 Recent Oncology PartnershipsAugust 23rd, 2024
- Lenox Hill Hospital Names New Chief of Breast Medical OncologyJuly 25th, 2021
- Join now to see all
Grant Support
- Degradomic And Peptidomic Biomarkers For Early-Stage Breast CancerNational Center For Research Resources2011
- Fatty Acid Synthase And EGFR/HER2 Cross-Talk In Breast Cancer CellsNational Center For Research Resources2009–2011
- Liposomal BCL-2 Antisense Therapy For Solid TumorsNational Cancer Institute1999–2003
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
External Links
- Perlmutter Cancer Center at NYUhttp://cancer.med.nyu.edu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
